Primary esophageal CD30-positive ALK-positive anaplastic large cell lymphoma: a case report and literature review.
OBJECTIVE
To introduce a case of primary esophageal CD30-positive ALK-positive anaplastic large cell lymphoma (ALCL) and discuss its diagnosis and treatment.


METHODS
Esophagectomy was done for a 37-year-old male with a submucosal lesion after a frozen section failed to give a definite diagnosis. Samples were sent for hematoxylin-eosin staining and immunohistochemical analysis. Six cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy were given and the patient was followed up.


RESULTS
The operation was uneventful. Postoperative pathologic and immunohistochemical examination yielded a diagnosis of primary CD30-positive and ALK-positive ALCL of the esophagus. The patient was in complete remission at the 14-month follow-up.


CONCLUSIONS
ALCL of the esophagus should be considered in the differential diagnosis of esophageal submucosal lesions. Biopsy through either esophagoscopy or surgical exploration, chemotherapy, and radiotherapy can be chosen for long-term survival.
Wu
Ning
N
Department of Cardiothoracic Surgery, Huashan Hospital, Fudan University, Shanghai, 200040, People's Republic of China.
Pang
Liewen
L
Chen
Zhiming
Z
Wang
Yiqing
Y
Ma
Qinyun
Q
Chen
Gang
G
Chen
Ji
J
Huang
Jiechun
J
D000328:Adult; D000077548:Anaplastic Lymphoma Kinase; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D007124:Immunoenzyme Techniques; D017730:Ki-1 Antigen / Q000378:metabolism*; D017728:Lymphoma, Large-Cell, Anaplastic / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D008297:Male; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D011241:Prednisone / Q000627:therapeutic use; D020794:Receptor Protein-Tyrosine Kinases / Q000378:metabolism*; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
D017730:Ki-1 Antigen; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases; D011241:Prednisone